BofA analyst Tazeen Ahmad initiated coverage of Ocular Therapeutix with a Buy rating and $15 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OCUL:
- Ocular Therapeutix Updates Phase 3 SOL Trial Protocol
- Ocular Therapeutix announces FDA agreement to amend SPA for AXPAXLI
- Summer Road raises Ocular Therapeutix stake by $5.0M
- Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
- Ocular Therapeutix 30.8M share Spot Secondary priced at $3.25
